Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of “Hold” by Analysts

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received an average recommendation of “Hold” from the twenty analysts that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $11.53.

Several analysts recently issued reports on the company. Oppenheimer decreased their target price on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating on the stock in a research note on Wednesday, October 30th. Raymond James reissued a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. Bank of America decreased their target price on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research note on Wednesday, October 9th. TD Cowen decreased their target price on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, November 21st. Finally, Truist Financial decreased their target price on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a research note on Wednesday, October 30th.

Hedge Funds Weigh In On Sage Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SAGE. Headlands Technologies LLC boosted its holdings in shares of Sage Therapeutics by 245.3% in the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after purchasing an additional 2,782 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 4,672 shares during the period. Creative Planning purchased a new position in shares of Sage Therapeutics in the 3rd quarter worth approximately $88,000. Quest Partners LLC boosted its holdings in shares of Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock worth $128,000 after purchasing an additional 1,486 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Sage Therapeutics during the 3rd quarter valued at $146,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Stock Up 12.2 %

NASDAQ SAGE opened at $5.61 on Wednesday. The stock’s 50-day moving average price is $6.07 and its 200-day moving average price is $8.14. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $28.26. The company has a market capitalization of $343.18 million, a P/E ratio of -1.01 and a beta of 0.87.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. During the same period last year, the business earned ($2.81) EPS. The firm’s quarterly revenue was up 337.1% compared to the same quarter last year. Research analysts anticipate that Sage Therapeutics will post -6.53 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.